Analyst Marie Thibault from BTIG maintained a Buy rating on Boston Scientific (BSX – Research Report) and keeping the price target at $120.00.
Marie Thibault has given her Buy rating due to a combination of factors including the recent FDA clearance for the Bolt Intravascular Lithotripsy (IVL) System, which Boston Scientific is set to acquire. This clearance, achieved through the 510(k) pathway, is a positive development that suggests potential growth opportunities for Boston Scientific in the vascular intervention market.
Additionally, the successful outcomes from the RESTORE ATK trial, which demonstrated no major adverse events and high procedural success, further support the potential of the Bolt IVL System. The ongoing evaluation of the system in the FRACTURE IDE study for coronary arterial disease also indicates a promising future for its broader applications. These developments collectively enhance the growth prospects of Boston Scientific, justifying the Buy rating.
In another report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $118.00 price target.
Based on the recent corporate insider activity of 134 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year.